Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-15

Clinical Trial Update: Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing safety and tolerability of AGN-199201 for erythema associated with rosacea has completed with posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-199201

Snippet

Sponsor: Allergan | Conditions: Rosacea, Erythema | Phase 1 | Status: COMPLETED | Results posted: 2013-11-15